Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vitrectomy for Branch Retinal Vein Occlusion

This study has been completed.
Sponsor:
Information provided by:
Shinjo Ophthalmologic Institute
ClinicalTrials.gov Identifier:
NCT00685490
First received: May 22, 2008
Last updated: May 23, 2008
Last verified: May 2008

May 22, 2008
May 23, 2008
July 1995
Not Provided
Reporting of the long term outcomes of PPV, with and without ILM peeling, in eyes with persistent macular edema secondary to BRVO [ Time Frame: 11 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00685490 on ClinicalTrials.gov Archive Site
Elevate the effectiveness of ILM peeling [ Time Frame: 11 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Vitrectomy for Branch Retinal Vein Occlusion
Vitrectomy for Persistent Macular Edema in Branch Retinal Vein Occlusion

To evaluate the long term outcomes of pars plana vitrectomy (PPV), with and without internal limiting membrane (ILM) peeling, in eyes with persistent macular edema secondary to branch retinal vein occlusion (BRVO).

Results suggest the following hypothesis:

  • PPV, with and without ILM peeling, appears to be beneficial in eyes with persistent macular edema due to BRVO
  • Effectiveness is maintained long term
  • ILM peeling does not significantly affect postoperative best corrected visual acuity (BCVA)
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

70 consecutive patients who underwent PPV, with and without OLM peeling, for persistent macular edema associted with BRVO

Vitrectomy
Procedure: Vitrectomy w/o ILM peeling for macular edema with BRVO
Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
Surgical
Retrospective chart review of 70 eyes of 70 consecutive patients who underwent PPV, with and without ILM peeling, for persistent macular edema associated with BRVO
Intervention: Procedure: Vitrectomy w/o ILM peeling for macular edema with BRVO
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
November 2006
Not Provided

Inclusion Criteria:

  • duration of symptoms lasting 27 weeks

Exclusion Criteria:

  • vitreous hemorrhage
  • severe cataract
  • biomicroscopic vitreomacular traction and epiretinal membrane
  • previous vitreoretinal surgery
  • other ocular diseases that could contribute to visual loss.
  • patients with macular branch vein occlusion
  • patients with a history of previous grid laser photocoagulation
Both
45 Years to 86 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00685490
KK-R-207-430R1, Kumagai BRVO
Yes
Kazuyuki Kumagai, Shinjo Ophthalmologic Institute
Shinjo Ophthalmologic Institute
Not Provided
Principal Investigator: Kazuyuki Kumagai, MD Shinjo Ophthalmologic Institute
Shinjo Ophthalmologic Institute
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP